Tracey G Simon1, Ann-Sofi Duberg1, Soo Aleman1, Raymond T Chung1, Andrew T Chan1, Jonas F Ludvigsson1. 1. From the Division of Gastroenterology and Hepatology (T.G.S., R.T.C., A.T.C.) and the Clinical and Translational Epidemiology Unit (T.G.S., A.T.C.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School (T.G.S., R.T.C., A.T.C.), Broad Institute (R.T.C., A.T.C.), and the Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health (A.T.C.) - all in Boston; the Department of Infectious Diseases, School of Medical Sciences, Faculty of Medicine and Health (A.-S.D.), and the Department of Pediatrics (J.F.L.), Örebro University Hospital, Örebro, and the Department of Infectious Diseases, Karolinska University Hospital (S.A.), the Department of Medicine Huddinge (S.A.), and the Department of Medical Epidemiology and Biostatistics (J.F.L.), Karolinska Institutet, Stockholm - all in Sweden; and the Department of Medicine, Columbia University College of Physicians and Surgeons, New York (J.F.L.).
Abstract
BACKGROUND: More information is needed about the long-term effects of low-dose aspirin (≤160 mg) on incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection. METHODS: Using nationwide Swedish registries, we identified all adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 2015 and who did not have a history of aspirin use (50,275 patients). Patients who were starting to take low-dose aspirin (14,205 patients) were identified by their first filled prescriptions for 90 or more consecutive doses of aspirin. We constructed a propensity score and applied inverse probability of treatment weighting to balance baseline characteristics between groups. Using Cox proportional-hazards regression modeling, we estimated the risk of hepatocellular carcinoma and liver-related mortality, accounting for competing events. RESULTS: With a median of 7.9 years of follow-up, the estimated cumulative incidence of hepatocellular carcinoma was 4.0% among aspirin users and 8.3% among nonusers of aspirin (difference, -4.3 percentage points; 95% confidence interval [CI], -5.0 to -3.6; adjusted hazard ratio, 0.69; 95% CI, 0.62 to 0.76). This inverse association appeared to be duration-dependent; as compared with short-term use (3 months to <1 year), the adjusted hazard ratios were 0.90 (95% CI, 0.76 to 1.06) for 1 to less than 3 years of use, 0.66 (95% CI, 0.56 to 0.78) for 3 to less than 5 years of use, and 0.57 (95% CI, 0.42 to 0.70) for 5 or more years of use. Ten-year liver-related mortality was 11.0% among aspirin users and 17.9% among nonusers (difference, -6.9 percentage points [95% CI, -8.1 to -5.7]; adjusted hazard ratio, 0.73 [95% CI, 0.67 to 0.81]). However, the 10-year risk of gastrointestinal bleeding did not differ significantly between users and nonusers of aspirin (7.8% and 6.9%, respectively; difference, 0.9 percentage points; 95% CI, -0.6 to 2.4). CONCLUSIONS: In a nationwide study of patients with chronic viral hepatitis in Sweden, use of low-dose aspirin was associated with a significantly lower risk of hepatocellular carcinoma and lower liver-related mortality than no use of aspirin, without a significantly higher risk of gastrointestinal bleeding. (Funded by the National Institutes of Health and others.).
BACKGROUND: More information is needed about the long-term effects of low-dose aspirin (≤160 mg) on incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection. METHODS: Using nationwide Swedish registries, we identified all adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 2015 and who did not have a history of aspirin use (50,275 patients). Patients who were starting to take low-dose aspirin (14,205 patients) were identified by their first filled prescriptions for 90 or more consecutive doses of aspirin. We constructed a propensity score and applied inverse probability of treatment weighting to balance baseline characteristics between groups. Using Cox proportional-hazards regression modeling, we estimated the risk of hepatocellular carcinoma and liver-related mortality, accounting for competing events. RESULTS: With a median of 7.9 years of follow-up, the estimated cumulative incidence of hepatocellular carcinoma was 4.0% among aspirin users and 8.3% among nonusers of aspirin (difference, -4.3 percentage points; 95% confidence interval [CI], -5.0 to -3.6; adjusted hazard ratio, 0.69; 95% CI, 0.62 to 0.76). This inverse association appeared to be duration-dependent; as compared with short-term use (3 months to <1 year), the adjusted hazard ratios were 0.90 (95% CI, 0.76 to 1.06) for 1 to less than 3 years of use, 0.66 (95% CI, 0.56 to 0.78) for 3 to less than 5 years of use, and 0.57 (95% CI, 0.42 to 0.70) for 5 or more years of use. Ten-year liver-related mortality was 11.0% among aspirin users and 17.9% among nonusers (difference, -6.9 percentage points [95% CI, -8.1 to -5.7]; adjusted hazard ratio, 0.73 [95% CI, 0.67 to 0.81]). However, the 10-year risk of gastrointestinal bleeding did not differ significantly between users and nonusers of aspirin (7.8% and 6.9%, respectively; difference, 0.9 percentage points; 95% CI, -0.6 to 2.4). CONCLUSIONS: In a nationwide study of patients with chronic viral hepatitis in Sweden, use of low-dose aspirin was associated with a significantly lower risk of hepatocellular carcinoma and lower liver-related mortality than no use of aspirin, without a significantly higher risk of gastrointestinal bleeding. (Funded by the National Institutes of Health and others.).
Authors: Jessica L Petrick; Vikrant V Sahasrabuddhe; Andrew T Chan; Michael C Alavanja; Laura E Beane-Freeman; Julie E Buring; Jie Chen; Dawn Q Chong; Neal D Freedman; Charles S Fuchs; John Michael Gaziano; Edward Giovannucci; Barry I Graubard; Albert R Hollenbeck; Lifang Hou; Eric J Jacobs; Lindsay Y King; Jill Koshiol; I-Min Lee; Martha S Linet; Julie R Palmer; Mark P Purdue; Lynn Rosenberg; Catherine Schairer; Howard D Sesso; Alice J Sigurdson; Jean Wactawski-Wende; Anne Zeleniuch-Jacquotte; Peter T Campbell; Katherine A McGlynn Journal: Cancer Prev Res (Phila) Date: 2015-09-21
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Vikrant V Sahasrabuddhe; Munira Z Gunja; Barry I Graubard; Britton Trabert; Lauren M Schwartz; Yikyung Park; Albert R Hollenbeck; Neal D Freedman; Katherine A McGlynn Journal: J Natl Cancer Inst Date: 2012-11-28 Impact factor: 13.506
Authors: Mohsen Malehmir; Dominik Pfister; Suchira Gallage; Marta Szydlowska; Donato Inverso; Elena Kotsiliti; Valentina Leone; Moritz Peiseler; Bas G J Surewaard; Dominik Rath; Adnan Ali; Monika Julia Wolf; Hannah Drescher; Marc E Healy; Daniel Dauch; Daniela Kroy; Oliver Krenkel; Marlene Kohlhepp; Thomas Engleitner; Alexander Olkus; Tjeerd Sijmonsma; Julia Volz; Carsten Deppermann; David Stegner; Patrick Helbling; César Nombela-Arrieta; Anahita Rafiei; Martina Hinterleitner; Marcel Rall; Florian Baku; Oliver Borst; Caroline L Wilson; Jack Leslie; Tracy O'Connor; Christopher J Weston; Abhishek Chauhan; David H Adams; Lozan Sheriff; Ana Teijeiro; Marco Prinz; Ruzhica Bogeska; Natasha Anstee; Malte N Bongers; Mike Notohamiprodjo; Tobias Geisler; Dominic J Withers; Jerry Ware; Derek A Mann; Hellmut G Augustin; Alexandros Vegiopoulos; Michael D Milsom; Adam J Rose; Patricia F Lalor; Josep M Llovet; Roser Pinyol; Frank Tacke; Roland Rad; Matthias Matter; Nabil Djouder; Paul Kubes; Percy A Knolle; Kristian Unger; Lars Zender; Bernhard Nieswandt; Meinrad Gawaz; Achim Weber; Mathias Heikenwalder Journal: Nat Med Date: 2019-04-01 Impact factor: 53.440
Authors: Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn Journal: Nat Rev Dis Primers Date: 2021-01-21 Impact factor: 52.329